Charles Dougherty, Jr., MS, JD
Chief Executive Officer
Charles (Chip) Dougherty is the Chief Executive Officer of Vivasc Therapeutics. With over 30 years in the life sciences industry and over 20 as an intellectual property attorney advising the industry, his expertise in the design, development, and commercial implementation of new technology is instrumental in leading Vivasc toward clinical trials.
Dr. Maliha Zahid, MD, PhD
Chief Scientific Officer
Dr. Maliha Zahid is the Chief Scientific Officer of Vivasc Therapeutics. As a practicing non-invasive, board-certified cardiologist and researcher, her expertise is the cornerstone of the company. She discovered the Cardiac Targeting Peptide (CTP) during her PhD program and has worked with this peptide both scientifically and commercially to identify the most appropriate use of this technology. Her work led to her receiving the inaugural University of Pittsburgh Innovation Institute Emerging Innovator Award.
Matthew Captline, MS
Executive Vice President of Operations
Matthew Captline is the Executive Vice President of Operations of Vivasc Therapeutics. He helped lead the Vivasc team through the Fall 2018 National Science Foundation's I-Corps program to identify commercial use cases for the Cardiac Targeting Peptide. His experience in the business and healthcare fields provides trusted insight for company growth.
Daniel Deaver, PhD
Advisor- Preclinical Strategy
Dr. Daniel (Dan) Deaver's professional career spans over 35 years and includes extensive experience in academia and the biopharmaceutical industry. He retired from Alkermes as Vice-President of Nonclinical R&D in 2016 after 17 years with the company. At Alkermes, he was actively involved in the oversight of medicinal chemistry, pharmacology, and toxicology efforts directed towards expanding Alkermes' internal drug portfolio. He was directly involved with four programs that lead to marketed drugs – Vivitrol®, Bydureon®, Aristada® and VumerityTM.
Advisor- Finance and Strategy
Ian Magazine has been a founder, finance, and operating executive and investor, developing and growing multiple early-stage emerging technology companies from startup through maturity and exit. Ian is best known for his work at Nextel, where he was the 1st employee and a founding member of Nextel’s Senior Management team.
Dr. Walid Saliba, MD
Dr. Walid Saliba is the Director of the Electrophysiology Lab, Associate Section Head of the Pacing and Electrophysiology Section, Co-Director of the Ventricular Arrhythmia Center, Medical Director of the Center for Atrial Fibrillation, and a Staff Cardiologist in the Section of Cardiac Electrophysiology and Pacing in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic.
He is board-certified in cardiac electrophysiology, cardiovascular disease, and internal medicine. Dr. Saliba is trained in all aspects of clinical cardiac electrophysiology and pacing, including catheter ablation of complex arrhythmias, implantation of cardiac pacemakers and defibrillators, placement of left atrial occlusion devices and extraction of implanted pacemaker- and ICD leads using laser technology.
Dr. Jerome E. Granato, MD, MBA
Advisor- Cardiology and Business
Dr. Jerome E. Granato recently retired as Senior Vice President and Medical Director of the National Cardiovascular Service Line for CommonSpirit Health, the largest non-profit healthcare provider in the United States.
In a 35 year career, he has actively participated in patient care, clinical and basic research, and hospital administration. He has served on the boards of directors of several national organizations, including the Texas Heart Institute. He is a graduate of the Johns Hopkins University School of Medicine and holds an MBA degree from the J.L. Kellogg Graduate School of Management from Northwestern University.